Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Erasca is a clinical-stage precision oncology company focused on developing therapies targeting the RAS/MAPK pathway, a key driver in many cancers. Its pipeline includes small and large molecule therapeutics, such as pan-RAF, RAS, and EGFR inhibitors, aimed at treating high unmet medical needs across diverse tumor types. The company emphasizes combination regimens to shut down cancer signaling pathways and improve patient outcomes.
This description was generated via AI from an annual report. Updated about 1 year ago.